- Bioequivalence of canakinumab liquid pre-filled syringe and reconstituted lyophilized formulations following 150 mg subcutaneous administration: a randomized study in healthy subjectsAndrea Chioato
Novartis Institutes for BioMedical Research, Translational Medicine, 4002, Basel, Switzerland
Clin Drug Investig 33:801-8. 2013..A new formulation (solution for injection as pre-filled syringe) has been developed to avoid reconstitution...
- Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center studyA Chioato
Novartis Institutes for BioMedical Research, Basel, Switzerland
Clin Vaccine Immunol 19:1597-602. 2012..A protective (≥4-fold) immune response to both vaccinations at 4 weeks was achieved in 80 and 76% of subjects exposed to secukinumab and the control, respectively...
- Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center studyA Chioato
Novartis Institutes for BioMedical Research, Translational Science, CH 4002 Basel, Switzerland
Clin Vaccine Immunol 17:1952-7. 2010..We concluded that a single dose of 300 mg canakinumab s.c. does not affect the induction or persistence of antibody responses after vaccination with unadjuvanted influenza or alum-adjuvanted MenC vaccines in healthy subjects...